Lung Cancer

Paul K. Paik, MD, clinical director of the Thoracic Oncology Service, Memorial Sloan Kettering Cancer Center, discusses how the potential approval of lorlatinib may alter the landscape for patients with ALK-positive non–small cell lung cancer (NSCLC).

Lyudmila Bazhenova, MD, professor of clinical medicine, University of California, San Diego, discusses the potential approval of lorlatinib for patients with ALK-positive non–small cell lung cancer (NSCLC).

The FDA has granted a priority review to a supplemental biologics license application for atezolizumab for use in combination with bevacizumab, carboplatin, and paclitaxel for the first-line treatment of patients with metastatic nonsquamous non–small cell lung cancer.

Sai-Hong I. Ou, MD, professor, Division of Hematology/Oncology, Department of Medicine, University of California, Irvine, discusses the use of crizotinib (Xalkori) in the treatment of patients with ROS1-rearranged non–small cell lung cancer (NSCLC).

Sandip P. Patel, MD, medical oncologist, assistant professor of medicine, University of California, San Diego, discusses novel agents for the treatment of patients with non–small cell lung cancer (NSCLC).

A supplemental biologics license application has been submitted to the FDA for the use of pembrolizumab in combination with standard chemotherapy as a treatment for patients with metastatic squamous non–small cell lung cancer.

Alice T. Shaw, MD, PhD, associate professor of medicine, Harvard Medical School, attending physician, Thoracic Cancer Program, Massachusetts General Hospital, discusses lorlatinib in the treatment of patients with lung cancer.

James Urbanic, MD, associate professor, Radiation Medicine and Applied Sciences, University of California, San Diego, discusses the role of radiotherapy in oligometastatic non–small cell lung cancer (NSCLC).

Edward B. Garon, MD, director of Thoracic Oncology at the Jonsson Comprehensive Cancer Center at University of California, Los Angeles, discusses immunotherapy combinations in non–small cell lung cancer.

The FDA has granted a priority review to a supplemental biologics license application for frontline pembrolizumab for use in combination with standard chemotherapy for patients with metastatic nonsquamous non–small cell lung cancer.

The European Medicines Agency’s Committee for Medicinal Products for Human Use has recommended approval of osimertinib as a first-line treatment for patients with non–small cell lung cancer (NSCLC) whose tumors harbor activating EGFR mutations.

Charles M. Rudin, MD, PhD, discusses ongoing developments with immunotherapy in patients with non–small cell lung cancer.

Mark G. Kris, MD, discusses the continued significance of chemotherapy in patients with NSCLC in the era of targeted agents and immunotherapy.

Charles M. Rudin, MD, PhD, chief, Thoracic Oncology Service, co-director, Druckenmiller Center for Lung Cancer Research, Sylvia Hassenfeld Chair in Lung Cancer Research, Memorial Sloan Kettering Cancer Center, discusses biomarkers for immunotherapy in lung cancer.

Dual immune checkpoint blockade with durvalumab (Imfinzi) and tremelimumab did not induce a statistically significant improvement in overall survival in heavily pretreated patients with locally-advanced or metastatic NSCLC.

Helena A. Yu, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatments for EGFR-mutant lung cancer.

Paul K. Paik, MD, discusses treatment advances and sequencing strategies for patients with ALK-positive NSCLC.

Helena A. Yu, MD, discusses sequencing strategies in EGFR-mutant NSCLC, the impact of osimertinib in the frontline setting, and the questions surrounding dacomitinib’s intriguing data in this landscape.

Matthew D. Hellmann, MD, discusses the expansion of biomarkers across single-agent and combination therapies in patients with non–small cell lung cancer.